Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1093)
•••
Post by Duster340on Jul 13, 2022 9:14am
115 Views
Post# 34820220

What is the meaning of this? head scratcher

What is the meaning of this? head scratcherobviously coordinated. i see a total of 121.6k sold and 82k bought for a -39.6k

Filing
DateTransaction
DateInsider NameOwnership
TypeSecuritiesNature of transactionVolume or ValuePriceJul 12/22Jul 12/22Wallace, John LawrenceDirect OwnershipCommon Shares10 - Disposition in the public market-30,500$0.620
Jul 12/22Jul 12/22Legault, Daniel MarcelDirect OwnershipCommon Shares10 - Acquisition in the public market30,000$0.620
Jul 12/22Jul 11/22Wallace, John LawrenceDirect OwnershipCommon Shares10 - Disposition in the public market-41,500$0.620
Jul 12/22Jul 11/22Wallace, John LawrenceDirect OwnershipCommon Shares10 - Disposition in the public market-20,000$0.600
Jul 12/22Jul 11/22Legault, Daniel MarcelDirect OwnershipCommon Shares10 - Acquisition in the public market24,500$0.620
Jul 12/22Jul 11/22Legault, Daniel MarcelDirect OwnershipCommon Shares10 - Acquisition in the public market7,500$0.600
Jul 12/22Jul 8/22Wallace, John LawrenceDirect OwnershipCommon Shares10 - Disposition in the public market-8,500$0.620
Jul 12/22Jul 8/22Wallace, John LawrenceDirect OwnershipCommon Shares10 - Disposition in the public market-5,100$0.610
Jul 12/22Jul 8/22Wallace, John LawrenceDirect OwnershipCommon Shares10 - Disposition in the public market-16,000$0.600
Jul 12/22Jul 8/22Curtis, Scott WilsonDirect OwnershipCommon Shares10 - Acquisition in the public market20,000$0.620
Sign up or login above to see all SEDI filings within the past 6 months.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities